TY - JOUR
T1 - Selective decontamination of the digestive tract and selective oropharyngeal decontamination in intensive care unit patients
T2 - A cost-effectiveness analysis
AU - Oostdijk, Evelien A.N.
AU - De Wit, G. A.
AU - Bakker, Marina
AU - De Smet, Anne Marie G.A.
AU - Bonten, M. J.M.
AU - the Dutch SOD-SDD trialists group
AU - Thijsen, Steven
PY - 2013
Y1 - 2013
N2 - Objective: To determine costs and effects of selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD) as compared with standard care (ie, no SDD/SOD (SC)) from a healthcare perspective in Dutch Intensive Care Units (ICUs). Design: A post hoc analysis of a previously performed cluster-randomised trial (NEJM 2009;360:20). Setting: 13 Dutch ICUs. Participants: Patients with ICU-stay of <48 h that received SDD (n≥2045), SOD (n≥1904) or SC (n≥1990). Interventions: SDD or SOD. Primary and secondary outcome measures: Effects were based on hospital survival, expressed as crude Life Years Gained (cLYG). The incremental costeffectiveness ratio (ICER) was calculated, with corresponding cost acceptability curves. Sensitivity analyses were performed for discount rates, costs of SDD, SOD and mechanical ventilation. Results: Total costs per patient were €41 941 for SC (95% CI €40 184 to €43 698), €40 433 for SOD (95% CI €38 838 to €42 029) and €41 183 for SOD (95% CI €39 408 to €42 958). SOD and SDD resulted in crude LYG of +0.04 and +0.25, respectively, as compared with SC, implying that both SDD and SOD are dominant (ie, cheaper and more beneficial) over SC. In cost-effectiveness acceptability curves probabilities for cost-effectiveness, compared with standard care, ranged from 89% to 93% for SOD and from 63% to 72% for SDD, for acceptable costs for 1 LYG ranging from €0 to €20 000. Sensitivity analysis for mechanical ventilation and discount rates did not change interpretation. Yet, if costs of the topical component of SDD and SOD would increase 40-fold to €400/day and €40/day (maximum values based on free market prices in 2012), the estimated ICER as compared with SC for SDD would be €21 590 per LYG. SOD would remain cost-saving. Conclusions: SDD and SOD were both effective and cost-saving in Dutch ICUs.
AB - Objective: To determine costs and effects of selective digestive tract decontamination (SDD) and selective oropharyngeal decontamination (SOD) as compared with standard care (ie, no SDD/SOD (SC)) from a healthcare perspective in Dutch Intensive Care Units (ICUs). Design: A post hoc analysis of a previously performed cluster-randomised trial (NEJM 2009;360:20). Setting: 13 Dutch ICUs. Participants: Patients with ICU-stay of <48 h that received SDD (n≥2045), SOD (n≥1904) or SC (n≥1990). Interventions: SDD or SOD. Primary and secondary outcome measures: Effects were based on hospital survival, expressed as crude Life Years Gained (cLYG). The incremental costeffectiveness ratio (ICER) was calculated, with corresponding cost acceptability curves. Sensitivity analyses were performed for discount rates, costs of SDD, SOD and mechanical ventilation. Results: Total costs per patient were €41 941 for SC (95% CI €40 184 to €43 698), €40 433 for SOD (95% CI €38 838 to €42 029) and €41 183 for SOD (95% CI €39 408 to €42 958). SOD and SDD resulted in crude LYG of +0.04 and +0.25, respectively, as compared with SC, implying that both SDD and SOD are dominant (ie, cheaper and more beneficial) over SC. In cost-effectiveness acceptability curves probabilities for cost-effectiveness, compared with standard care, ranged from 89% to 93% for SOD and from 63% to 72% for SDD, for acceptable costs for 1 LYG ranging from €0 to €20 000. Sensitivity analysis for mechanical ventilation and discount rates did not change interpretation. Yet, if costs of the topical component of SDD and SOD would increase 40-fold to €400/day and €40/day (maximum values based on free market prices in 2012), the estimated ICER as compared with SC for SDD would be €21 590 per LYG. SOD would remain cost-saving. Conclusions: SDD and SOD were both effective and cost-saving in Dutch ICUs.
UR - http://www.scopus.com/inward/record.url?scp=84876113055&partnerID=8YFLogxK
U2 - 10.1136/bmjopen-2012-002529
DO - 10.1136/bmjopen-2012-002529
M3 - Article
AN - SCOPUS:84876113055
SN - 2044-6055
VL - 3
JO - BMJ open
JF - BMJ open
IS - 3
M1 - 002529
ER -